BG108337A - Използване на остеопонтин за лечение и/или профилактика на неврологични заболявания - Google Patents
Използване на остеопонтин за лечение и/или профилактика на неврологични заболявания Download PDFInfo
- Publication number
- BG108337A BG108337A BG108337A BG10833703A BG108337A BG 108337 A BG108337 A BG 108337A BG 108337 A BG108337 A BG 108337A BG 10833703 A BG10833703 A BG 10833703A BG 108337 A BG108337 A BG 108337A
- Authority
- BG
- Bulgaria
- Prior art keywords
- osteopontin
- polypeptide
- disease
- cells
- brain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Psychiatry (AREA)
- Biochemistry (AREA)
- Psychology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01111296 | 2001-05-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
BG108337A true BG108337A (bg) | 2004-12-30 |
Family
ID=8177366
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BG108337A BG108337A (bg) | 2001-05-17 | 2003-11-10 | Използване на остеопонтин за лечение и/или профилактика на неврологични заболявания |
Country Status (27)
Country | Link |
---|---|
US (4) | US7217687B2 (de) |
EP (1) | EP1389130B1 (de) |
JP (2) | JP4417632B2 (de) |
KR (1) | KR100947424B1 (de) |
CN (2) | CN1286524C (de) |
AT (1) | ATE555803T1 (de) |
AU (1) | AU2002312886B2 (de) |
BG (1) | BG108337A (de) |
BR (1) | BR0209812A (de) |
CA (1) | CA2443964A1 (de) |
CZ (1) | CZ20033109A3 (de) |
EA (1) | EA006655B1 (de) |
EE (1) | EE200300559A (de) |
ES (1) | ES2387082T3 (de) |
HK (1) | HK1067051A1 (de) |
HR (1) | HRP20030840A2 (de) |
HU (1) | HUP0400005A3 (de) |
IL (2) | IL158867A0 (de) |
MX (1) | MXPA03010327A (de) |
NO (1) | NO20035025D0 (de) |
NZ (1) | NZ528852A (de) |
PL (1) | PL211763B1 (de) |
SK (1) | SK14232003A3 (de) |
UA (1) | UA85368C2 (de) |
WO (1) | WO2002092122A2 (de) |
YU (1) | YU89503A (de) |
ZA (1) | ZA200307956B (de) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7202044B2 (en) | 2001-05-09 | 2007-04-10 | Biovision Ag | Method for detecting a progressive, chronic dementia disease, and corresponding peptides and detection agents |
AU2002357748A1 (en) * | 2001-11-21 | 2003-06-10 | The Board Of Trustees Of The Leland Stanford Junior University | Osteopontin-related compositions and methods |
EP1517695A4 (de) * | 2002-06-25 | 2010-09-01 | Aventis Pharma Inc | Osteopontin, oligodendrozyten und myelinierung |
WO2004013311A2 (en) * | 2002-08-06 | 2004-02-12 | Diadexus, Inc. | Compositions and methods relating to ovarian specific genes and proteins |
BRPI0408889A (pt) * | 2003-03-28 | 2006-04-11 | Applied Research Systems | uso de clusterina para o tratamento e/ou prevenção de doenças neurológicas periféricas |
RU2379975C2 (ru) * | 2003-09-18 | 2010-01-27 | Арла Фудс Амба | Добавка в состав для детского питания |
EP2301569B1 (de) * | 2003-11-12 | 2018-05-02 | Yeda Research and Development Co. Ltd. | Impfstoff und Verfahren zur Behandlung neurodegenerativer Krankheiten |
US7790687B2 (en) | 2005-02-18 | 2010-09-07 | Proximagen Ltd. | Treatment for neurodegeneration |
US20060264371A1 (en) * | 2005-02-18 | 2006-11-23 | Proximagen Ltd. | Treatment |
CA2624916A1 (en) | 2005-10-13 | 2007-04-26 | Anthrogenesis Corporation | Production of oligodendrocytes from placenta-derived stem cells |
EP1870107A1 (de) * | 2006-06-23 | 2007-12-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Verwendung eines PML Auslöser zur Behandlung von neurodegenerativen Krankheiten mit Polyglutamine Vermehrung |
WO2008086449A2 (en) * | 2007-01-09 | 2008-07-17 | Oregon Health & Science University | Synthetic osteopontin peptides and methods of use |
US20100069254A1 (en) * | 2008-09-16 | 2010-03-18 | Laree Hiser | Cell Culture Model for Demyelination/Remyelination |
KR101449100B1 (ko) * | 2011-04-21 | 2014-10-13 | 가톨릭대학교 산학협력단 | 신경세포 데브리스 제거용 오스테오폰틴 |
GB2493540A (en) * | 2011-08-10 | 2013-02-13 | Follicum Ab | Agents for stimulating hair growth in mammals |
WO2014051398A1 (ko) * | 2012-09-28 | 2014-04-03 | 한국생명공학연구원 | 아세카이니드 또는 이의 유도체를 포함하는 근력약화 관련 질환의 예방 또는 치료용 약학적 조성물 |
EP3186274B1 (de) * | 2014-08-27 | 2021-10-06 | Dana-Farber Cancer Institute, Inc. | Intrazelluläres osteopontin zur regulierung des lineage-commitments von lymphoiden untergruppen |
JP2019519515A (ja) | 2016-05-20 | 2019-07-11 | シーダーズ—シナイ メディカル センター | アルツハイマー病およびアルツハイマー病に関係する疾病を処置または予防する方法 |
US10954280B2 (en) * | 2016-11-27 | 2021-03-23 | Triton Algae Innovations, Inc. | Method of purification of recombinant osteopontin from micro algae |
JP2020518556A (ja) | 2017-05-04 | 2020-06-25 | フォリクム エービー | 糖尿病の処置のためのペプチド |
WO2019036331A1 (en) * | 2017-08-15 | 2019-02-21 | The Children's Medical Center Corporation | OSTEOPONTIN AS A TREATMENT OF NEURONAL INJURIES |
TR201903865A2 (tr) * | 2019-03-14 | 2020-09-21 | Bogazici Ueniversitesi | Amyotrofi̇k lateral skleroz tedavi̇si̇ i̇çi̇n i̇nterferon kullanimi |
WO2021024265A1 (en) * | 2019-08-08 | 2021-02-11 | Ramot At Tel-Aviv University Ltd. | Methods of treating non-infectious inflammatory disorders |
CN111388654A (zh) * | 2020-05-22 | 2020-07-10 | 南通大学 | 治疗脊髓损伤的药物、药物试剂盒及方法 |
EP4159223A4 (de) * | 2020-06-02 | 2024-07-17 | Catholic Univ Korea Ind Academic Cooperation Foundation | Zusammensetzung mit osteopontinhemmer als wirkstoff zur prävention, linderung oder behandlung von neurodegenerativen erkrankungen |
CN117720620A (zh) * | 2023-12-13 | 2024-03-19 | 无锡市儿童医院 | 小分子多肽和其药物组合物、其制药用途 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000037502A2 (en) | 1998-12-22 | 2000-06-29 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists and uses thereof |
IL145891A0 (en) | 1999-04-15 | 2002-07-25 | Childrens Medical Center | Methods and compositions for modulating an immune response |
WO2000064460A2 (en) * | 1999-04-23 | 2000-11-02 | Sulzer Orthopedics Ltd. | Composition for enhancing functional recovery of a mammal from central and/or peripheral nervous system injury of traumatic or pathological origin |
AU782298B2 (en) * | 1999-10-04 | 2005-07-14 | Nektar Therapeutics | Polymer stabilized neuropeptides |
-
2002
- 2002-05-08 EA EA200301253A patent/EA006655B1/ru not_active IP Right Cessation
- 2002-05-08 EE EEP200300559A patent/EE200300559A/xx unknown
- 2002-05-08 SK SK1423-2003A patent/SK14232003A3/sk unknown
- 2002-05-08 CN CNB028144627A patent/CN1286524C/zh not_active Expired - Fee Related
- 2002-05-08 KR KR1020037014773A patent/KR100947424B1/ko not_active IP Right Cessation
- 2002-05-08 CN CNA2006101317669A patent/CN1939538A/zh active Pending
- 2002-05-08 AU AU2002312886A patent/AU2002312886B2/en not_active Ceased
- 2002-05-08 YU YU89503A patent/YU89503A/sh unknown
- 2002-05-08 AT AT02738042T patent/ATE555803T1/de active
- 2002-05-08 CZ CZ20033109A patent/CZ20033109A3/cs unknown
- 2002-05-08 US US10/477,876 patent/US7217687B2/en not_active Expired - Fee Related
- 2002-05-08 UA UA20031110269A patent/UA85368C2/ru unknown
- 2002-05-08 NZ NZ528852A patent/NZ528852A/en not_active IP Right Cessation
- 2002-05-08 HU HU0400005A patent/HUP0400005A3/hu unknown
- 2002-05-08 BR BR0209812-1A patent/BR0209812A/pt not_active IP Right Cessation
- 2002-05-08 MX MXPA03010327A patent/MXPA03010327A/es active IP Right Grant
- 2002-05-08 EP EP02738042A patent/EP1389130B1/de not_active Expired - Lifetime
- 2002-05-08 JP JP2002589038A patent/JP4417632B2/ja not_active Expired - Fee Related
- 2002-05-08 CA CA002443964A patent/CA2443964A1/en not_active Abandoned
- 2002-05-08 WO PCT/EP2002/005081 patent/WO2002092122A2/en active Application Filing
- 2002-05-08 PL PL367065A patent/PL211763B1/pl not_active IP Right Cessation
- 2002-05-08 ES ES02738042T patent/ES2387082T3/es not_active Expired - Lifetime
- 2002-05-08 IL IL15886702A patent/IL158867A0/xx unknown
-
2003
- 2003-10-13 ZA ZA200307956A patent/ZA200307956B/en unknown
- 2003-10-15 HR HR20030840A patent/HRP20030840A2/hr not_active Application Discontinuation
- 2003-11-10 BG BG108337A patent/BG108337A/bg unknown
- 2003-11-12 NO NO20035025A patent/NO20035025D0/no not_active Application Discontinuation
- 2003-11-13 IL IL158867A patent/IL158867A/en not_active IP Right Cessation
-
2004
- 2004-11-05 US US10/981,737 patent/US7297099B2/en not_active Expired - Fee Related
- 2004-12-22 HK HK04110138A patent/HK1067051A1/xx not_active IP Right Cessation
-
2007
- 2007-02-27 US US11/679,735 patent/US20070225214A1/en not_active Abandoned
- 2007-11-07 US US11/936,623 patent/US20080213234A1/en not_active Abandoned
-
2009
- 2009-06-05 JP JP2009136621A patent/JP5036761B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5036761B2 (ja) | 神経疾患の治療及び/又は予防のためのオステオポンチンの使用 | |
AU2002312886A1 (en) | Use of osteopontin for the treatment and/or prevention of neurologic diseases | |
KR20050119149A (ko) | 말초 신경 질환의 치료 및/또는 예방을 위한 클루스테린의용도 | |
EP1799248B1 (de) | Verwendung von il-17f zur behandlung und/oder prävention von neurologischen erkrankungen | |
JP5048658B2 (ja) | 神経性炎症性疾患の治療、及び/又は予防のためのil−18bpアイソフォームの使用 |